John Frye

963 total citations · 1 hit paper
24 papers, 754 citations indexed

About

John Frye is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John Frye has authored 24 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in John Frye's work include Renal cell carcinoma treatment (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cardiac Arrhythmias and Treatments (3 papers). John Frye is often cited by papers focused on Renal cell carcinoma treatment (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cardiac Arrhythmias and Treatments (3 papers). John Frye collaborates with scholars based in United States, New Zealand and Spain. John Frye's co-authors include Ravi Salgia, Mark J. Ratain, Razelle Kurzrock, David S. Hong, Linda Janisch, Steven I. Sherman, Robert F. Gagel, Ezra E.W. Cohen, Chaan S. Ng and Arlene A. Forastiere and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Cancer.

In The Last Decade

John Frye

23 papers receiving 735 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

2011 445 citations Razelle Kurzrock, Steven I. Sherman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Frye United States	10	286	230	222	172	148	24	754
Francesca Del Monte Italy	17	458 1.6×	129 0.6×	306 1.4×	168 1.0×	112 0.8×	27	1.0k
Kiyohiko Dohi Japan	14	168 0.6×	54 0.2×	183 0.8×	257 1.5×	132 0.9×	43	751
Maura O’Neil United States	16	245 0.9×	67 0.3×	275 1.2×	65 0.4×	118 0.8×	46	795
Marilyn Mulay United States	11	365 1.3×	134 0.6×	243 1.1×	250 1.5×	37 0.3×	17	644
Jaymes Holland United States	14	259 0.9×	71 0.3×	294 1.3×	299 1.7×	65 0.4×	25	769
Koichi Suyama Japan	12	273 1.0×	50 0.2×	159 0.7×	157 0.9×	83 0.6×	48	706
Johanna Wassermann France	12	197 0.7×	167 0.7×	77 0.3×	83 0.5×	80 0.5×	41	514
Jaume Capdevila Spain	18	277 1.0×	758 3.3×	150 0.7×	158 0.9×	29 0.2×	41	1.0k
Daishu Toya Japan	14	170 0.6×	79 0.3×	124 0.6×	104 0.6×	91 0.6×	31	540
Nicolas Poté France	16	285 1.0×	86 0.4×	184 0.8×	148 0.9×	342 2.3×	45	922

Countries citing papers authored by John Frye

Since Specialization

Citations

This map shows the geographic impact of John Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Frye more than expected).

Fields of papers citing papers by John Frye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Frye. The network helps show where John Frye may publish in the future.

Co-authorship network of co-authors of John Frye

This figure shows the co-authorship network connecting the top 25 collaborators of John Frye. A scholar is included among the top collaborators of John Frye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Frye. John Frye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frye, John, et al.. (2021). Crisis Standards of Care Guidelines for the COVID-19 Pandemic: Fresno Resource Allocation Guide (FRAG). Cureus. 13(11). e19662–e19662. 1 indexed citations

Burris, Howard A., Alexander I. Spira, Matthew H. Taylor, et al.. (2021). A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2516–2516. 22 indexed citations

Stroh, Mark, Rachel Li, Hong Lu, et al.. (2020). Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009: A masked probody drug conjugate to CD166.. Journal of Clinical Oncology. 38(15_suppl). 3599–3599.

Frye, John, et al.. (2020). Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula.. PubMed. 24(4). 322–326. 4 indexed citations

Hari, Parameswaran, Claudia E. Paba‐Prada, Peter M. Voorhees, et al.. (2019). Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leukemia Research. 83. 106172–106172. 15 indexed citations

Cunningham, Thomas V., et al.. (2019). Comprehensive Quality Assessment in Clinical Ethics. The Journal of Clinical Ethics. 30(3). 284–296. 5 indexed citations

Frye, John, et al.. (2018). Aortoduodenal syndrome: a rare cause of duodenal obstruction in a patient with previous aortic aneurysm repair. ANZ Journal of Surgery. 89(10). E476–E477. 2 indexed citations

Frye, John & Stuart J. Youngner. (2016). A Call for a Patient-Centered Response to Legalized Assisted Dying. Annals of Internal Medicine. 165(10). 733–734. 6 indexed citations

Nokihara, Hiroshi, Nobuyuki Yamamoto, Shinji Nakamichi, et al.. (2012). Molecular Profile and Anti-Tumor Activity in Non-Small Cell Lung Cancer (NSCLC) Patients (PTS) in a Phase 1 Study of Cabozantinib (XL184) in Japan. Annals of Oncology. 23. ix174–ix174. 2 indexed citations

10.

Kurzrock, Razelle, Steven I. Sherman, Douglas W. Ball, et al.. (2011). Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology. 29(19). 2660–2666. 445 indexed citations breakdown →

11.

Kurzrock, Razelle, Scott K. Sherman, David S. Hong, et al.. (2008). 379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC). European Journal of Cancer Supplements. 6(12). 119–119. 20 indexed citations

12.

Salgia, Ravi, et al.. (2007). A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Molecular Cancer Therapeutics. 6. 8 indexed citations

13.

Anthony, A, et al.. (2002). Nutritional and immune status following spinal cord injury: a case controlled study. Spinal Cord. 40(12). 627–630. 18 indexed citations

14.

Venook, Alan P., Linda D. Ferrell, John P. Roberts, et al.. (1995). Liver transplantation for hepatocellular carcinoma: Results with preoperative chemoembolization. Liver Transplantation and Surgery. 1(4). 242–248. 63 indexed citations

15.

Small, Eric J., John Frye, Mary Wilkinson, et al.. (1994). A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer. 73(11). 2803–2807. 2 indexed citations

16.

Frye, John, Alan P. Venook, James W. Ostroff, et al.. (1992). Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump. Gastrointestinal Endoscopy. 38(1). 52–54. 7 indexed citations

17.

Lynch, Joseph J., Andrew C. G. Uprichard, John Frye, et al.. (1989). Effects of the Positive Inotropic Agents Milrinone and Pimobendan on the Development of Lethal Ischemic Arrhythmias in Conscious Dogs with Recent Myocardial Infarction. Journal of Cardiovascular Pharmacology. 14(4). 585–597. 21 indexed citations

18.

Uprichard, Andrew C. G., Liguo Chi, Joseph J. Lynch, et al.. (1989). Alinidine Reduces the Incidence of Ischemic Ventricular Fibrillation in a Conscious Canine Model, a Protective Effect Antagonized by Overdrive Atrial Pacing. Journal of Cardiovascular Pharmacology. 14(3). 475–482. 8 indexed citations

19.

Uprichard, Andrew C. G., Liguo Chi, Jan M. Kitzen, et al.. (1989). Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.. Journal of Pharmacology and Experimental Therapeutics. 251(2). 571–577. 5 indexed citations

20.

Stoddard, Frederick J., et al.. (1951). Replacement Transfusion Following Administration of Incompatible Blood. Anesthesia & Analgesia. 30(1). 353–353. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact